Media
SCROLL DOWN FOR THE LATEST PRESS RELEASES AND TWEETS For media enquiries about any aspect of the work of the PMCPA please contact the Press Office via the switchboard: 020 7747 8880 or email us at info@pmcpa.org.uk Sign up for eAlerts at the top of the page Follow us on Twitter @PMCPAUK
The PMCPA publishes certain Sanctions (advertisements, public reprimands and corrective statements) Press Releases, Case Reports and Code of Practice Reviews.
- the carrying out by the PMCPA of an audit of a company’s procedures to comply with the Code. This can also be followed by a requirement that promotional material be submitted to the PMCPA for pre-vetting for a specified period
- requiring the company to take steps to recover items from those to whom they have been given
- requiring the company to issue a corrective statement
- a public reprimand
- suspension or expulsion from membership of the ABPI.
Where companies are ruled in breach of Clause 2 of the Code, and/or are required to issue a corrective statement and/or are the subject of a public reprimand, the PMCPA advertises brief details of the cases in the medical, nursing and pharmaceutical press, the advertisements are also published on this website.
Case Reports (access Case Reports here)
As mentioned above, in some cases a company may be required to issue a corrective statement or may be the subject of a public reprimand or advertisements in the medical and pharmaceutical press.
Code of Practice Review (access Code of Practice Reviews here)The Code of Practice Review is published quarterly by the PMCPA. It includes the case reports of all cases completed within the previous three months, new advice that has been issued on the Code and an editorial relating to current matters of interest.
News
all news-
Forthcoming 2021 ABPI Code
15 January 2021
read more -
New Chair of the Code of Practice Appeal Board
11 December 2020
read more -
The PMCPA is recruiting
05 October 2020
read more -
Colonis Pharma has been named in advertisements for breaches of ABPI Code.
25 September 2020
read more -
Merck Sharp & Dohme, Gilead Sciences Europe, Daiichi-Sankyo and Allergan have been named in advertisements for breaches of ABPI Code.
25 September 2020
read more -
Pfizer and Bristol Myers Squibb, The Alliance, named in advertisements for breaches of the ABPI Code of Practice
25 September 2020
read more